We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

16 hedge funds and large institutions have $3.17M invested in Moleculin Biotech in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital inflows, than outflows

Capital inflows: $59.1K | Capital outflows: $50.9K

0.02% more ownership

Funds ownership: 10.43% → 10.45% (+0.02%)

6% less funds holding

Funds holding: 17 → 16 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$42.2K
2
Virtu Financial
Virtu Financial
New York
+$16.9K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$21K
2
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$12K
3
BlackRock
BlackRock
New York
-$8.44K
4
Osaic Holdings
Osaic Holdings
Arizona
-$8.44K
5
Almanack Investment Partners
Almanack Investment Partners
Pennsylvania
-$1K

MBRX Hedge Fund Activity: Q4 2022 in Review

16 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2022, worth a combined $3.17M — up 0.35% from $3.16M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of MBRX and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest buyer was Charles Schwab, opening a new position worth an estimated $42.2K. The largest seller was Jane Street, exiting entirely with an estimated $21K sold.

  • 16 institutional investors held Moleculin Biotech (MBRX) as of Q4 2022, down from 17 in Q3 2022.
  • Funds reported $3.17M of Moleculin Biotech stock for Q4 2022, up 0.35% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q4 2022 and 3 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q4 2022 was Charles Schwab, an estimated $42.2K added.
  • The largest Moleculin Biotech seller in Q4 2022 was Jane Street, an estimated $21K sold.

Based on aggregated 13F filings for Q4 2022.